^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ERCC1 negative

    i
    Other names: ERCC1, RAD10, Excision repair cross-complementation group 1
    Entrez ID:
    2067
    Related biomarkers:
    Expression
    Mutation
    CNA
    over3years
    Extensive analysis of the molecular biomarkers excision repair cross complementing 1, ribonucleotide reductase M1, β-tubulin III, thymidylate synthetase, and topoisomerase IIα in breast cancer: Association with clinicopathological characteristics. (PubMed, Medicine (Baltimore))
    The expression intensity of TOP2A positively associated with that of TYMS. Hierarchical clustering analysis and difference test indicated that breast cancer with higher levels of TUBB3, TYMS, and TOP2A, as well as lower levels of ERCC1 and RRM1 tended to have higher histological grade and Ki-67 index.Our studies showed that ERCC1, TYMS, TUBB3, and TOP2A may be potential biomarkers for prognosis and individualized chemotherapy guidance, while there may be interactions between ERCC1 and RRM1, or TUBB3, or TYMS, as well as between TOP2A and TYMS in pathogenesis and development of breast cancer.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • TOP2A (DNA topoisomerase 2-alpha) • ERCC1 (Excision repair cross-complementation group 1) • TUBB3 (Tubulin beta 3 class III) • TYMS (Thymidylate Synthetase) • RRM1 (Ribonucleotide Reductase Catalytic Subunit M1)
    |
    EGFR expression • ERCC1 negative • TOP2A expression
    almost4years
    A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. (PubMed, Cancers (Basel))
    Patients treated with nCRT (paclitaxel, carboplatin) and esophagectomy received six 21-day cycles with oxaliplatin (130 mg/m) on day 1 and S-1 (25 mg/m twice daily) on days 1-14...To conclude, six cycles adjuvant S-1 and oxaliplatin were not feasible in pretreated esophageal adenocarcinoma. Although the question remains whether additional treatment with chemotherapy should be provided in the adjuvant setting, subgroups such as patients with ERCC1 negativity could potentially benefit from adjuvant SOX based on our exploratory biomarker research.
    Clinical • P2 data • Journal
    |
    ERCC1 (Excision repair cross-complementation group 1) • TYMS (Thymidylate Synthetase)
    |
    ERCC1 negative
    |
    carboplatin • paclitaxel • 5-fluorouracil • oxaliplatin